Alaunos Therapeutics, Inc.
Income Statement
| Line Item | FY2010 | FY2009 | FY2008 | FY2007 | FY2006 | FY2005 | FY2004 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — |
| Operating Expenses | |||||||
| Research & Development | $12.9M | $4.6M | — | — | — | — | — |
| SG&A Expense | $11.6M | $7.6M | — | — | — | $45.0K | $251.0K |
| Operating Income | $-24.5M | $-12.1M | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — |
| Net Income | $-32.7M | $-7.6M | $-25.2M | $-26.6M | $-17.9M | $-9.5M | $-5.7M |
| Net Margin | — | — | — | — | — | — | — |
| EPS (Basic) | $-0.71 | $-0.33 | — | — | — | — | — |
| EPS (Diluted) | $-0.71 | $-0.33 | — | — | — | — | — |
| Shares Outstanding (Basic) | 48.5M | — | — | — | — | — | — |
| Shares Outstanding (Diluted) | 48.5M | — | — | — | — | — | — |
| Dividends Per Share | — | — | — | — | — | — | — |